Delivering on the Vision: a Flashback to the 2021 Alvo kickoff

The pandemic was a tough time for everyone, including our companies and teams. But it was also a time when we proved our mettle, staying true to our mission to serve patients and our vision of the Alvo family growing into global leaders. 

This short video from the early days of 2021 is a blast from the past, but I think an illuminating one. The spirit and determination that we showed then has borne fruit in our achievements today.

In July, we announced the sale of a majority stake in Adalvo to EQT. Alvogen has continued its role as a leading speciality pharma platform in the U.S., with over 50 marketed products, including brands and generics. And as Lotus continues to win recognition for its successes , in September it acquired Alvogen as a subsidiary, making Lotus a top 20 global specialty pharma.

No less notably, Alvotech has grown up from the 'teenager' I described back then. At that time, we were just breaking ground on the extension of our manufacturing facility. Today, we are realizing our ambition to make Alvotech a global leader in biosimilars. We have two products on global markets, expect to launch more in the before the end of this year, and have one of the most valuable pipelines in the industry.

We still are and will continue to be no less ambitious than we were five years ago. We continue to deliver on the vision, which remains as consistent and clear as ever: to develop world-leading companies that can improve access to life-changing medicines for people around the world.